Pharmacology of antidepressants

Elliott Richelson

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Presently in the United States, 21 compounds have been approved by the Food and Drug Administration as antidepressants. Two additional drugs marketed outside the United States as antidepressants have been approved for obsessive-compulsive disorder. Nearly one half of all these compounds became available within the past 12 years, whereas the first antidepressant was available more than 40 years ago. After the clinical aspects of depression are introduced in this article, the pharmacology of the newer generation drugs is reviewed in relationship to the older compounds. The information in this review will help clinicians treat acute depression with pharmacological agents.

Original languageEnglish (US)
Pages (from-to)511-527
Number of pages17
JournalMayo Clinic Proceedings
Volume76
Issue number5
StatePublished - 2001

Fingerprint

Antidepressive Agents
Pharmacology
Depression
Obsessive-Compulsive Disorder
United States Food and Drug Administration
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Richelson, E. (2001). Pharmacology of antidepressants. Mayo Clinic Proceedings, 76(5), 511-527.

Pharmacology of antidepressants. / Richelson, Elliott.

In: Mayo Clinic Proceedings, Vol. 76, No. 5, 2001, p. 511-527.

Research output: Contribution to journalArticle

Richelson, E 2001, 'Pharmacology of antidepressants', Mayo Clinic Proceedings, vol. 76, no. 5, pp. 511-527.
Richelson E. Pharmacology of antidepressants. Mayo Clinic Proceedings. 2001;76(5):511-527.
Richelson, Elliott. / Pharmacology of antidepressants. In: Mayo Clinic Proceedings. 2001 ; Vol. 76, No. 5. pp. 511-527.
@article{c38e0293ceee42fda4ea3fb685977566,
title = "Pharmacology of antidepressants",
abstract = "Presently in the United States, 21 compounds have been approved by the Food and Drug Administration as antidepressants. Two additional drugs marketed outside the United States as antidepressants have been approved for obsessive-compulsive disorder. Nearly one half of all these compounds became available within the past 12 years, whereas the first antidepressant was available more than 40 years ago. After the clinical aspects of depression are introduced in this article, the pharmacology of the newer generation drugs is reviewed in relationship to the older compounds. The information in this review will help clinicians treat acute depression with pharmacological agents.",
author = "Elliott Richelson",
year = "2001",
language = "English (US)",
volume = "76",
pages = "511--527",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "5",

}

TY - JOUR

T1 - Pharmacology of antidepressants

AU - Richelson, Elliott

PY - 2001

Y1 - 2001

N2 - Presently in the United States, 21 compounds have been approved by the Food and Drug Administration as antidepressants. Two additional drugs marketed outside the United States as antidepressants have been approved for obsessive-compulsive disorder. Nearly one half of all these compounds became available within the past 12 years, whereas the first antidepressant was available more than 40 years ago. After the clinical aspects of depression are introduced in this article, the pharmacology of the newer generation drugs is reviewed in relationship to the older compounds. The information in this review will help clinicians treat acute depression with pharmacological agents.

AB - Presently in the United States, 21 compounds have been approved by the Food and Drug Administration as antidepressants. Two additional drugs marketed outside the United States as antidepressants have been approved for obsessive-compulsive disorder. Nearly one half of all these compounds became available within the past 12 years, whereas the first antidepressant was available more than 40 years ago. After the clinical aspects of depression are introduced in this article, the pharmacology of the newer generation drugs is reviewed in relationship to the older compounds. The information in this review will help clinicians treat acute depression with pharmacological agents.

UR - http://www.scopus.com/inward/record.url?scp=0035025833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035025833&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 511

EP - 527

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 5

ER -